Radiotherapy Center Cluj S.R.L. — Clinical Trial Site

98 Registered trials

38 Currently recruiting

Organisation

Radiotherapy Center Cluj S.R.L.

Location

Floresti, Romania

Identifier

ORG-100041797

Address

Strada Oitelor 7, 040278, Romania

Departments

040005: Oncology
2304:Oncology
3203: Oncology
3203:oncology
40004: Oncology
6101: Oncology
6103:Oncology
93150001: Oncology
Departament Clinic Oncologie Medicala
Departament Oncologie Medicala
Medical Oncology
Medical Oncology Department
N/A
NA
Oncologie
Oncologie Medicala
Oncologie Medicala - Radioterapie
Oncology
Radiology Center
ROU005: Oncology
Sectia Oncologie Medicala
Specialitatea Oncologie Medicala

Clinical trials at this site (98)

Search interface

Avelumab Program Rollover Study Ended

2024-514274-46-00 Solid Tumors 5 2019-06-21
A Study of Zolbetuximab (IMAB362) plus CAPOX in Adults with Gastric Cancer. Ended

2024-511648-16-00 Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Adv 5 2019-01-04
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
CheckMate 274 Ended

2022-500630-29-00 Subjects with High Risk Invasive Urothelial Carcinoma 5 2016-05-06
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted

2023-508730-34-00 Non-small cell lung cancer (NSCLC): - Locally advanced 9 2024-07-10
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati… Ended

2023-506882-70-00 Non-small-cell lung cancer 5 2024-08-16
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended

2023-505712-37-00 The participants must have a histologically confirmed d 10 2024-06-06
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Recurrent or advanced/metastatic solid tumors who are i 4 2023-11-27
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants with Advanced/Metastatic Non-Sq… Ended

2022-500608-23-00 Previously Untreated MET Amplified Locally Advanced/Met 4 2023-04-06
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with… Ended

2022-502752-31-00 Non-small cell lung cancer 11 2022-04-29
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Participants with completely resected Stage III or Stag 5 2021-12-03
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Esophageal Carcinoma 5 2021-07-21
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Lung Cancer, Non-Small Cell 4 2020-11-25
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17
This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended

2022-502747-35-00 Newly diagnosed advanced (FIGO stage III-IV) high grade 5 2019-02-18
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended

2023-509360-24-00 Subjects with resected adenocarcinoma or squamous cell 5 2016-06-16